Orthocell Ltd (ASX:OCC, OTC:ORHHF) CEO and managing director Paul Anderson earlier this week spoke with Proactive after the company reported record revenue for the June 2025 quarter, citing strong uptake of its flagship Remplir nerve repair product.
Highlights
- Orthocell reported record quarterly revenue of A$2.73 million for June 2025, up 22.8% on the prior quarter.
- Growth was driven by accelerated sales of the flagship nerve repair device, Remplir, in Australia.
- Over 206 surgeons across 166 hospitals in Australia are now using Remplir.
- The company has developed a network of key opinion leaders and partnerships with centers of excellence.
- Orthocell has recruited 14 distributors with over 100 representatives covering 21 US states.
- The first procedure using Remplir was completed in the United States last week.
- Future revenue growth is expected as the US market begins contributing sales.
- The company anticipates increased product adoption and further hospital engagement over the next financial year.
“Spectacular” success
The company said quarterly revenue reached A$2.73 million, representing a 22.80 percent increase compared to the previous quarter. Orthocell highlighted that this growth reflected continued adoption across Australia, with more than 206 surgeons now using Remplir in over 166 hospitals.
Anderson told investors that the commercial launch in Australia has been a “spectacular” success. The company noted that none of the reported revenue was generated in the United States, where it recently completed its first procedure.
Orthocell said it has established a distribution network in the US, comprising 14 distributors and more than 100 representatives across 21 states. The company expects this infrastructure will drive further growth as the product is adopted by additional hospitals and surgeons.
International scale
Anderson stated that preparations over the past two years have positioned the company to scale internationally. He said, “It leaves us in such a strong position,” adding that the lessons learned in Australia will inform the US commercial rollout.
Potential catalysts for investors include increased US revenue contributions, further hospital engagements, and broader clinical use of Remplir. Orthocell also expects rising adoption rates in Australia to continue contributing to revenue momentum over the coming financial year.